AstraZeneca Terminates Their License Agreement with Allergan for Brazikumab Signed in 2016
AstraZeneca Terminates Their License Agreement with Allergan for Brazikumab Signed in 2016
Shots:
- AstraZeneca has completed its agreement with Allergan to recover the global rights to brazikumab (formerly MEDI2070). Both the companies have terminated their 2016 agreement and all rights to brazikumab, now returned to AstraZeneca
- Allergan to fund up to an agreed amount, estimated to be the total costs expected to be incurred by AstraZeneca until completion of the development of brazikumab for CD and UC, including the development of a CDx
- Pursuant to 2012 collaboration with Amgen, AstraZeneca will grant royalties on sales of brazikumab, if approved and launched. Brazikumab is mAb targeting IL23 and is in development for CD and UC with a companion biomarker
Click here to read full press release/ article | Ref: AstraZeneca | Image: Zymewire work